Rosuvastatin
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
High-confidence LDL/ApoB lowering for cardiovascular risk reduction, with secondary hsCRP lowering and plaque-regression evidence at high-intensity doses.
Rosuvastatin is high-confidence lipid medicine, but it still needs baseline and follow-up lipids, muscle-symptom awareness, liver/glucose monitoring at higher doses, and pregnancy/lactation avoidance.
High-confidence LDL/ApoB lowering for cardiovascular risk reduction, with secondary hsCRP lowering and plaque-regression evidence at high-intensity doses. In PED contexts it is mainly protective infrastructure: a way to counter androgen-driven LDL rise and HDL suppression, not a performance enhancer.
Muscle pain or weakness is the practical day-to-day watch item; rhabdomyolysis is rare but serious. Higher doses add diabetes-risk signal, liver-enzyme monitoring, benign proteinuria risk at 40 mg, absolute pregnancy/lactation avoidance, and a real over-suppression problem when total cholesterol or LDL is driven too low during aggressive stacks.
Rosuvastatin is the strongest generic statin per milligram and has little CYP3A4 overlap, so it fits better than many statins in complex PED or longevity stacks. The tradeoff is that it only makes sense with baseline and follow-up lipids, dose discipline, and a willingness to back down if cholesterol is overshot.
Very high for LDL reduction: clinical trials and review data support roughly 35–65% dose-dependent LDL lowering, and community bloodwork reports generally match that range. The community stance is bullish but bounded: rosuvastatin is favored when lipid risk is real, but minimum effective dosing and retesting matter.
Intro
Rosuvastatin (brand name Crestor, now generic) is the most potent statin per milligram, classified as a high-intensity statin alongside atorvastatin at equivalent doses.
It works by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. By blocking this enzyme, rosuvastatin reduces mevalonate production, forces hepatocytes to upregulate LDL receptors, and pulls LDL particles from circulation into the liver for clearance.
Rosuvastatin's defining pharmacokinetic feature is its hydrophilicity. Unlike lipophilic statins such as atorvastatin or simvastatin, rosuvastatin does not readily penetrate the blood-brain barrier and minimally affects CYP3A4 enzyme activity. This translates into fewer drug-drug interactions with compounds that compete for CYP3A4 metabolism — a practically significant advantage for people running polypharmacy stacks — and reduced risk of cognitive side effects like brain fog that some users report with lipophilic statins.
In cardiovascular medicine, rosuvastatin demonstrated a landmark result in the JUPITER trial (n=17,802): a 44% reduction in major cardiovascular events in patients who had normal LDL but elevated high-sensitivity CRP, establishing that rosuvastatin's anti-inflammatory pleiotropic effects can deliver benefit independent of cholesterol levels. Beyond LDL reduction, it reduces hsCRP by approximately 37%, improves endothelial function, and has been shown to achieve coronary plaque regression in IVUS studies.
In the performance enhancement community, rosuvastatin has become the default on-cycle lipid management tool. Androgenic PEDs reliably suppress HDL by 30–50% and raise LDL by 20–40%, and the community consensus has settled on LDL <70 mg/dL as the target for PED users engaged in cardiovascular risk reduction. Rosuvastatin's combination of potent LDL reduction, low CNS penetration, and minimal CYP interaction makes it the rational first choice.
Observed Effects
LDL cholesterol reduction is the primary and most consistent effect. Clinical trials document dose-dependent LDL lowering: approximately 35% at 5 mg, 45% at 10 mg, 55% at 20 mg, and 60–65% at the maximum 40 mg dose.
Cochrane systematic review confirms this dose-response pattern across diverse populations.
Triglyceride levels typically fall 20–35%. HDL cholesterol increases modestly, approximately 8–14%. These combined lipid changes represent the cardiometabolic core of the drug's benefit.
Anti-inflammatory effects: the JUPITER trial documented a 37% reduction in hsCRP on 20 mg rosuvastatin in a population with normal LDL but elevated baseline hsCRP. This anti-inflammatory action operates through mechanisms beyond cholesterol — including endothelial function improvement and reduced oxidative stress — and may explain event reduction in patients who wouldn't qualify for statin therapy on LDL criteria alone.
Coronary plaque regression: meta-analysis of IVUS studies found rosuvastatin achieves greater plaque regression than atorvastatin at comparable high-intensity doses. Both drugs produced regression versus baseline, but rosuvastatin's advantage may reflect its stronger pleiotropic anti-inflammatory profile.
PED context: community data confirm rosuvastatin effectively counteracts the dyslipidemia of androgenic PEDs. Users report achieving LDL 40–70 mg/dL targets on 5–10 mg daily or 10 mg twice weekly protocols, even while running suppressive oral cycles. One documented community protocol paired rosuvastatin 10 mg twice weekly with ezetimibe 10 mg daily and projected LDL near 40 mg/dL from a baseline around 95 mg/dL.
Field Reports
Patient and user-reported outcomes are broadly consistent with clinical trial predictions. Patient communities regularly post before/after lipid panels showing 40–60% LDL reductions at 10 mg, aligning with trial averages.
Patients switching from atorvastatin to rosuvastatin report equivalent or better lipid control with fewer cognitive side effects in most anecdotal accounts.
Fatigue is the most reported side effect in patient communities, more than classic myalgia. Several tolerance reports describe users stopping because of leg weakness, then successfully resuming at lower doses or with alternate-day protocols plus CoQ10. This side effect pattern suggests mitochondrial/energy metabolism impacts at higher doses.
Long-term users (5–10+ years) report stable lipid control without dose escalation in the majority of cases. Individual variation in tolerability is substantial — some users report zero side effects on 20 mg while others cannot tolerate 5 mg. Drug holidays sometimes used to confirm statin causality of symptoms.
The athletic/running community describes mixed effects on training performance — some report increased fatigue and reduced recovery at 10–20 mg doses; others report no change. This heterogeneity is consistent with the individual variation in CoQ10 depletion sensitivity.
Generic rosuvastatin (post-2016 generic entry) eliminated cost as a barrier. The transition from brand-name Crestor to generic is generally reported as seamless — bioequivalent formulations.
Community Consensus
Rosuvastatin occupies a unique position in performance enhancement culture: it is one of the few mainstream prescription drugs adopted not as a performance enhancer, but as protective infrastructure.
In those circles it is often discussed alongside aromatase control, blood-pressure management, and post-cycle planning rather than alongside anabolic agents.
The community's drug intelligence on rosuvastatin is unusually aligned with clinical pharmacology. Discussions correctly identify hydrophilicity as the key differentiator from atorvastatin and simvastatin; the absence of meaningful CYP3A4 interaction; the appropriateness of sub-daily dosing given the 19-hour half-life; the LDL <70 mg/dL target for higher-risk PED users; the superiority of ezetimibe over niacin for most LDL-management problems; and the plausibility of cholesterol over-suppression at aggressive doses.
A consistent practitioner consensus has formed around rosuvastatin as the preferred statin when a statin is needed in a complex stack. The stance is not maximalist: the strongest thread is potent LDL control with minimum effective dosing, follow-up labs, and quick de-escalation if cholesterol drops below a useful floor.
A frequently referenced over-suppression case, with total cholesterol around 67 mg/dL on daily low-dose use while on cycle, functions as the cautionary anchor. The community uses it to argue for retesting and frequency reduction rather than maximal suppression.
Longevity users have independently arrived at low-dose rosuvastatin as a prevention tool, typically in cardiometabolic stacks at doses more conservative than PED on-cycle protocols.
Risks & Monitoring
Myopathy and muscle effects: myalgia (muscle pain, aching, weakness) occurs in approximately 5–10% of patients in real-world use, though RCT rates are lower.
Rhabdomyolysis — the severe form with CK >10× ULN — is rare (<0.1%) but requires immediate discontinuation and is the main serious safety concern. Individual variation is high: some users tolerate high doses without issue while others are sensitive to even low doses. Dose-dependent risk: 40 mg carries meaningfully higher myopathy risk than 5–10 mg. CoQ10 depletion through the mevalonate pathway is a proposed mechanism; community widely adds CoQ10/ubiquinol co-supplementation though RCT evidence is mixed.
New-onset diabetes: modestly elevated risk (~9% relative increase) with high-intensity statins including rosuvastatin. This is a class effect. Clinically relevant in prediabetic or metabolic syndrome patients. Monitoring glucose/HbA1c annually is standard at high doses.
Hepatic effects: transient mild transaminase elevations occur. Severe hepatotoxicity is rare. One GP-tracked case documented reversible ALT/AST elevation that normalized after discontinuation. Active liver disease is an absolute contraindication.
Proteinuria: dose-dependent benign increase in urinary protein at 40 mg (~3% rate). Mechanistically distinct from nephrotoxicity (increased glomerular filtration of low MW proteins, not tubular damage). Rarely requires discontinuation but warrants monitoring.
Cholesterol over-suppression: one community case documented total cholesterol of 67 mg/dL on daily 5 mg rosuvastatin while on cycle — considered too low. Cholesterol is required for cell membrane integrity, cell signaling, and hormone synthesis. The community response was to reduce frequency to 3×/week with retesting. There is a practical floor below which cholesterol suppression becomes counterproductive, especially during androgen cycles where steroidogenesis is relevant.
CNS effects: minimal compared to lipophilic statins. Brain fog is uncommon; community and clinical pharmacology both treat rosuvastatin as lower-CNS than lipophilic alternatives. One minority assertion suggests rosuvastatin may penetrate the BBB like pravastatin — this is contested in the broader literature.
Pregnancy: Category X — animal studies demonstrate teratogenicity. Absolute contraindication in pregnancy and breastfeeding.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish LDL baseline before initiating; used to set treatment target and assess response
Recheck 4–6 weeks after initiating or changing dose to assess LDL response and confirm target is reached or not over-suppressed
Baseline CK to detect pre-existing myopathy. Recheck if muscle symptoms develop; >10× ULN requires discontinuation
Baseline LFTs to rule out active liver disease (contraindication); monitor for hepatic effects at 3 months and annually
Recheck 3 months after initiation and annually; more frequent if PED-induced hepatic stress
Baseline metabolic status; statin-associated new-onset diabetes risk is relevant, especially in users with prediabetes or metabolic syndrome
Annual monitoring for statin-associated new-onset diabetes, particularly at 20–40 mg doses
Relevant if using rosuvastatin for anti-inflammatory indication (JUPITER population: normal LDL but elevated hsCRP). Track response to anti-inflammatory use.
Consider at 40 mg doses — benign dose-dependent proteinuria occurs in ~3% of 40 mg users. Not typically required at 5–10 mg.
Avoid With
Do not combine Rosuvastatin with the following. Sorted highest-severity first.
Why:Pharmacokinetic — gemfibrozil dramatically increases rosuvastatin AUC via OATP1B1 inhibition, raising systemic rosuvastatin exposure and markedly increasing myopathy/rhabdomyolysis risk
What to do:Gemfibrozil + rosuvastatin is contraindicated at higher doses. If a fibrate is needed for severe hypertriglyceridemia, use fenofibrate instead — it has no significant interaction with rosuvastatin.
Why:Cyclosporine is a potent inhibitor of hepatic drug transporters (OATP1B1) and CYP enzymes. Dramatically increases rosuvastatin plasma concentrations — up to 7-fold AUC increase. Severe myopathy risk.
What to do:Maximum rosuvastatin dose 5 mg/day when cyclosporine cannot be avoided. This interaction is in FDA labeling.
Why:Class effect — niacin + statin combination increases myopathy risk. Practical consensus also treats niacin's HDL increase as a weak surrogate when mortality benefit is absent, making niacin an inferior alternative to the rosuvastatin/ezetimibe combination for lipid management in PED users.
What to do:Avoid high-dose niacin (>1g) with rosuvastatin. Low-dose niacin (flush-free, <500 mg) is lower risk but not recommended over ezetimibe for lipid management.
Why:Pharmacodynamic — rosuvastatin can potentiate warfarin's anticoagulant effect, increasing INR. Clinically significant INR elevation has been reported when rosuvastatin is added to a warfarin regimen.
What to do:Monitor INR closely when initiating or changing rosuvastatin dose in warfarin users. INR adjustment typically required.
Protocols By Goal
On-cycle lipid management (PED users): Goal: LDL <70 mg/dL. Starting point: baseline lipid panel before cycle; recheck 3–4 weeks into cycle to quantify lipid changes.
Protocol: rosuvastatin 5–10 mg daily (or EOD for mild elevation) + ezetimibe 10 mg daily for dual-mechanism coverage. If LDL target not reached at 10 mg rosuvastatin, increase to 20 mg or add PCSK9 inhibitor (evolocumab/alirocumab) as next escalation. Monitor monthly or at cycle end.
Cardiovascular primary prevention (longevity/cardiometabolic approach): Goal: LDL <70 mg/dL or apoB <70 mg/dL. Rosuvastatin 5–10 mg daily as part of cardiometabolic stack: rosuvastatin + ezetimibe + omega-3 ± low-dose aspirin ± empagliflozin (SGLT2 inhibitor for kidney/metabolic protection). This is the prevention-oriented cardiometabolic core often used in longevity circles.
Anti-inflammatory (JUPITER indication — normal LDL, elevated hsCRP): Goal: hsCRP <2.0 mg/L. Protocol: rosuvastatin 20 mg daily. Track hsCRP at 3 months. This indication is well-supported by JUPITER trial data.
Familial hypercholesterolemia (FH): Goal: LDL <100 mg/dL (or <70 for high-risk FH). Rosuvastatin 20–40 mg daily + ezetimibe. PCSK9 inhibitors added when statin + ezetimibe ceiling is insufficient (common in severe FH with LDL 250–300+).
Tolerance optimization: If myalgia or fatigue develops: reduce dose, switch to every-other-day, add CoQ10 200 mg (ubiquinol form preferred), or switch to pitavastatin if rosuvastatin specifically problematic.
Dosing Details
Standard clinical dosing ranges from 5 mg to 40 mg once daily. General guidance:
5 mg: starting dose for Asian patients (pharmacokinetically different — 2× plasma exposure), elderly patients, or anyone initiating with significant interaction concerns. Achieves ~35% LDL reduction.
10 mg: standard starting dose for most patients. High-intensity classification (≥50% LDL reduction in many patients). 45% average LDL reduction.
20 mg: for patients requiring greater LDL reduction (very high cardiovascular risk, familial hypercholesterolemia). 55% average LDL reduction. JUPITER trial used 20 mg for the anti-inflammatory hsCRP indication.
40 mg: maximum FDA-approved dose. Reserved for severe/refractory hypercholesterolemia. Higher myopathy and proteinuria risk. Not commonly used in community settings.
Sub-daily dosing: the 19-hour half-life supports non-daily regimens. Community protocols that achieve meaningful LDL reduction: - 5 mg once weekly → ~23% LDL reduction (mild intervention only) - 5 mg every other day → ~39% LDL reduction (good for moderate on-cycle lipid elevation) - 10 mg 2×/week → LDL reduction predicted ~40–50 mg/dL absolute from moderate baseline when paired with ezetimibe - 5 mg 3×/week (Mon/Wed/Fri) → achieves moderate control and is commonly used to back off from over-suppression
Titration: start at intended dose and recheck lipid panel at 4–6 weeks. Increase by one dose level if LDL target not reached. Maximum 40 mg/day.
For PED users: initiate when on-cycle lipid changes have developed (typically 2–4 weeks into cycle). Continue during cycle. Many continue 4–8 weeks post-cycle or until lipids normalize on labs.
Stacks & Alternatives
The canonical companion to rosuvastatin. Ezetimibe blocks intestinal cholesterol absorption (NPC1L1 inhibitor) while rosuvastatin blocks hepatic synthesis — complementary, non-overlapping mechanisms produce additive LDL reduction of 60–70% combined. Community describes ezetimibe as the 'safest cholesterol medication' with essentially no side effects. 10 mg daily. Universally recommended for PED users as the first add-on to any statin.
Statins inhibit the mevalonate pathway upstream of CoQ10 synthesis, potentially depleting this mitochondrial electron transport chain cofactor. Community widely co-supplements 200 mg ubiquinol to counter statin-associated fatigue and myalgia. RCT evidence for clinical benefit is mixed but mechanistically plausible. Standard harm-reduction supplement addition.
Omega-3s reduce triglycerides (independent effect from statin) and have anti-inflammatory properties. Rosuvastatin + omega-3 provides complementary lipid management — statin for LDL, omega-3 for TG and anti-inflammatory. Part of the prevention-oriented cardiometabolic core stack.
SGLT2 inhibitor co-used for kidney protection in PED users exposed to androgenic stress, and for additional anti-inflammatory and metabolic benefits. Some cardiometabolic support protocols pair this class with statin and ezetimibe coverage. Not primarily for lipid management — the combination addresses multiple cardiovascular risk vectors simultaneously.
ARB commonly co-stacked with rosuvastatin for blood pressure management and renal protection in PED users. Telmisartan's PPAR-delta activity adds metabolic benefits. Rosuvastatin + telmisartan represents the cardiovascular protection double-header in the PED community.
Alternatives
Stack Cost
Low-to-moderate stack tax: rosuvastatin is cheap, oral, non-suppressive, non-injectable, and low-CYP, but it creates a real lab-management lane around lipids, muscle symptoms, glucose, liver context, pregnancy, and drug interactions.
The article repeatedly frames rosuvastatin as powerful enough to overshoot. Total cholesterol near 67 mg/dL or LDL below roughly 40 mg/dL is treated as a signal to reduce frequency and retest, not as a win.
Myalgia and fatigue are the main lived side effects. Rhabdomyolysis is rare, but CK becomes a stop-signal lab if muscle symptoms are severe or unusual.
The drug does not require endocrine recovery, but high-intensity dosing brings glucose/HbA1c attention, baseline liver context, and caution in active liver disease.
Rosuvastatin is easier than CYP3A4-heavy statins in polypharmacy stacks, but gemfibrozil, cyclosporine, high-dose niacin, warfarin, severe renal impairment, and SLCO1B1 exposure issues still matter.
There is no virilization or HPG suppression, but pregnancy and breastfeeding are hard avoid lanes because fetal development depends on cholesterol biology.
- ·Do not run rosuvastatin blind: get baseline lipids and recheck 4-6 weeks after initiation or dose change.
- ·If total cholesterol falls below about 100 mg/dL or LDL below about 40 mg/dL, reduce dose or frequency and retest rather than chasing lower numbers.
- ·Avoid gemfibrozil and keep cyclosporine co-use at prescriber-level dosing limits; these are exposure-driven myopathy risk lanes.
- ·Treat unexplained muscle weakness, dark urine, severe myalgia, or CK above 10x ULN as stop conditions.
- ·Use the 5 mg starting lane in Asian patients and cap at lower doses in severe renal impairment as described in the practical section.
- ·Creates a lipid-response feedback loop: baseline lipid panel, repeat at 4-6 weeks, and annual monitoring once stable.
- ·Often creates an ezetimibe decision if LDL/ApoB remains above target or if a lower statin dose is preferred.
- ·Creates symptom-contingent CK monitoring and optional CoQ10/ubiquinol support when fatigue or myalgia appears.
- ·In PED stacks, creates a cholesterol-floor check so lipid suppression does not become counterproductive during androgen exposure.
The molecule itself is not hormonally suppressive, anabolic, injectable, or acutely psychoactive. The beginner caveat is operational: correct use depends on lipid targets, retesting, pregnancy status where relevant, interaction review, and recognizing muscle or over-suppression signals.
- ·No baseline labs or no realistic follow-up testing
- ·Pregnant, breastfeeding, or actively trying to conceive
- ·Active liver disease, severe renal impairment without dose oversight, or prior statin rhabdomyolysis
- ·Complex anticoagulant, transplant, or fibrate regimen without prescriber monitoring
Practical Setup
Monitoring cadence: lipid panel at baseline and 4–6 weeks after initiation (or dose change), then annually when at stable dose. LFTs at baseline, 3 months, and annually. CK if muscle symptoms develop — don't check routinely without symptoms. HbA1c or fasting glucose annually.
Dosing realities for PED users: the community has effectively compressed the useful dose range to 5–20 mg. Below 5 mg (e.g., 2.5 mg daily or 5 mg once weekly) provides modest LDL reduction only suitable for mild baseline elevation. Above 20 mg adds myopathy risk without commensurate additional benefit in most users. The 5 mg EOD through 10 mg daily range covers most on-cycle applications.
Over-suppression awareness: cholesterol is required for steroidogenesis, cell membrane integrity, and cell signaling. If total cholesterol drops below 100 or LDL below 40 on standard doses, frequency reduction is appropriate — not dose doubling as an overcorrection. A documented community case with total cholesterol around 67 mg/dL is the practical reference for this concern.
Asian patients: FDA recommends starting at 5 mg maximum in Asian patients due to 2× higher plasma exposure. This applies regardless of use context.
Renal impairment: maximum 10 mg/day in severe renal impairment (CrCl <30 ml/min).
Transporter genetics: SLCO1B1 polymorphisms (particularly c.521T>C) reduce hepatic rosuvastatin uptake and increase systemic exposure — these patients have higher myopathy risk and may benefit from lower doses.
Fibrate combination: if adding a fibrate for severe hypertriglyceridemia, use fenofibrate not gemfibrozil. Gemfibrozil dramatically increases rosuvastatin exposure and is contraindicated or requires significant dose reduction.
Pitavastatin as alternative: if rosuvastatin is not tolerated, pitavastatin is the common lower-potency hydrophilic alternative — also low-CYP and often favored when the first goal is tolerability rather than maximum LDL reduction.
Mechanism Deep Dive
Rosuvastatin's primary mechanism is competitive, reversible inhibition of HMG-CoA reductase — the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step in the cholesterol biosynthesis pathway.
This inhibition is hepatoselective: rosuvastatin's hydrophilic structure and active uptake by hepatic OATP1B1 and OATP1B3 transporters concentrate it in the liver rather than systemic tissues, reducing off-target effects.
The downstream consequence of HMG-CoA inhibition: depleted intracellular cholesterol triggers SREBP-2 (sterol regulatory element-binding protein 2) cleavage and nuclear translocation, which upregulates LDL receptor expression on hepatocytes. More LDL receptors means greater clearance of circulating LDL particles into the liver — the mechanistic basis for LDL reduction.
The mevalonate pathway is upstream of multiple isoprenoid products beyond cholesterol: coenzyme Q10, dolichols, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate are all downstream. Depletion of CoQ10 — a critical component of mitochondrial electron transport chain complex I and II — is the leading mechanistic hypothesis for statin-associated myopathy. Rho protein geranylgeranylation inhibition may explain pleiotropic anti-inflammatory effects.
Pleiotropic mechanisms: rosuvastatin reduces hsCRP, improves endothelial nitric oxide synthase (eNOS) activity, reduces endothelin-1, decreases superoxide production, and has antithrombotic effects (reduced platelet aggregation, decreased PAI-1). These effects collectively explain the JUPITER trial finding — cardiovascular benefit in a population with normal LDL but elevated inflammatory tone.
Pharmacokinetics: oral bioavailability ~20% (extensive hepatic first-pass). Tmax 3–5 hours. Half-life approximately 19 hours. Highly protein-bound (~88%). Minimally metabolized (CYP2C9 minor; not CYP3A4). Primary elimination: feces (~90%, largely unchanged drug). Dose adjustment required in severe renal impairment (CrCl <30). SLCO1B1 pharmacogenomics influences hepatic exposure.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Rosuvastatin 20 mg reduced major cardiovascular events by 44% vs placebo in JUPITER trial
Trial stopped early at 1.9 years. Applies to the elevated-hsCRP/normal-LDL indication. Extrapolation to PED users or younger populations not directly validated.
Rosuvastatin reduces LDL 45–55% at 10–20 mg doses
Cochrane systematic review. Dose-dependent response consistent across populations. Individual variation ±10–15%.
Rosuvastatin achieves greater coronary plaque regression than atorvastatin
Meta-analysis of 5 RCTs. IVUS-measured plaque volume. Clinically meaningful endpoint — plaque regression reduces rupture risk. Not a mortality endpoint.
New-onset diabetes risk modestly elevated (~9% relative increase) with high-intensity statins
Class effect, not rosuvastatin-specific. Absolute risk small. Does not negate CV benefit in at-risk patients.
Rosuvastatin 5 mg every other day achieves ~39% LDL reduction; 5 mg once weekly achieves ~23%
Community-derived data consistent with half-life pharmacokinetics. Not RCT-validated but mechanistically plausible. Individual variation expected.
Androgenic PEDs decrease HDL ~50% and increase LDL ~30%
Practitioner consensus from PED community. Consistent with the known androgenic lipid effects documented in literature (HDL decrease reported across multiple small studies). Exact percentages are community estimates; actual effect varies by compound and dose.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.